1. The Pharmaceutical Research and Manufacturers of America, the American Medical Association, and other groups representing pharma and healthcare interests increased their federal lobbying spending during the first year of the Trump administration. PhRMA spent $25.4 million during 2017, a 30% jump over 2016. (Axios)

2. Bayer CEO Werner Baumann and incoming Novartis chief executive Vas Narasimhan were among 15 European business leaders who attended a private dinner with President Donald Trump in Davos, Switzerland. The event’s goal was to encourage the companies to make investments in the U.S. (Stat)

3. Gene-testing firm Illumina won a $26.7 million jury verdict in an action against rival Ariosa Diagnostics, which is owned by Roche. Illumina’s lawsuit claimed that Ariosa’s prenatal test kits infringed on Illumina patents. (Reuters)

4. Takeda said its diabetes drug Actos failed to show in a Phase III trial that it slowed Alzheimer’s symptoms. Eli Lilly, Pfizer, and Axovant have experienced similar failures in their efforts to develop new Alzheimer’s treatments. (Endpoints News)

5. McCann Health has promoted June Laffey to the new position of EVP, chief creative officer of McCann Health New York. Laffey, who chaired the Pharma jury at last year’s Cannes Health Lions, was previously regional executive creative director for McCann Health Australia and Southeast Asia.